# GPT-5.4 (R1) Review

**Role:** External referee review
**Model:** openai/gpt-5.4
**Paper:** paper.pdf
**Timestamp:** 2026-03-06T03:44:17.889502
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 18474 in / 4457 out
**Response SHA256:** c73c644c62b9df42

---

This paper asks an important policy question and engages a high-interest domain: whether examiner-driven variation in patenting affects subsequent green innovation. The paper is transparent that, because it only observes granted patents, it estimates a reduced-form effect of assignment to a “higher-output” examiner rather than a structural grant effect. That transparency is a strength. However, in its current form, the empirical design does not support the main causal interpretation, and the inference strategy for the main outcome is not yet convincing. The core problems are not cosmetic; they go to identification, estimand definition, and statistical validity. I therefore do not think the paper is publication-ready for a top general-interest outlet or AEJ: EP.

## 1. Identification and empirical design

### A. The central design does not isolate examiner “grant propensity”
The paper’s key regressor is a leave-one-out examiner grant share within art-unit-by-grant-year cells:
\[
Z_i = \frac{n_{j,a,t}-1}{N_{a,t}-1}
\]
(Data section; Empirical Strategy section).

This is not a grant rate. It is an examiner’s share of *observed grants* in a cell, computed using granted patents only. As the paper notes, it may reflect “differential case assignment volume” rather than differential grant propensity. That caveat is much more than a nuance; it is the central identification problem.

Within an art-unit-by-grant-year cell, an examiner can have a high grant share because:
1. they are more permissive;
2. they simply handled more applications;
3. they worked faster and disposed more cases;
4. they were assigned particular types of cases or workloads.

With granted-only data, these channels are not separable. As a result, the paper does not identify the effect of assignment to a more permissive examiner, nor even cleanly to a “higher-output examiner” in a way that is exogenous to assignment intensity.

This is especially problematic because the paper repeatedly frames the design as exploiting quasi-random assignment to examiners within art units “validated” by prior examiner-IV work. But those papers rely on application-level data with grant/deny information and a true first stage. Here, the instrument analogue is constructed from the selected sample of grants, so the connection to that literature is weaker than presented.

### B. Conditioning on granted patents creates severe selection concerns
The sample is limited to granted Y02 patents (Data section; Appendix sample construction). That means the analysis conditions on a post-assignment, post-examiner-decision outcome. This has two implications:

1. **Selection on treatment-induced survival into the sample**: if examiner behavior affects whether an application becomes a granted patent, then restricting to granted patents selects different types of applications under different examiner assignments. This undermines causal interpretation even for reduced-form estimates among grants.

2. **Balance tests on granted patents are not informative about random assignment of applications**: Table 2 regresses claims and backward citations on examiner grant share. But these variables are measured on granted patents only. Since claims and citations can themselves be affected by prosecution/examiner behavior, and the sample excludes denied/abandoned applications, these are not valid pre-treatment balance tests for assignment randomness. The paper treats small imbalances as reassuring; they are not.

The paper acknowledges the grants-only limitation, but the implications are understated. In current form, the main result is best interpreted as a descriptive association within the selected population of grants, not a credible causal estimate of examiner-driven patent output on follow-on innovation.

### C. The treatment timing/comparison cell choice is conceptually and empirically awkward
The regressor is constructed in **art-unit-by-grant-year** cells, while the main regressions include **art-unit-by-filing-year** fixed effects (Data and Empirical Strategy sections). The justification is that filing-year FE absorb cohort effects while grant-year cells capture “contemporaneous grant behavior.”

But this creates several problems:
- The relevant randomization, if any, occurs at application assignment, which is tied to filing/application timing, not grant-year.
- Examiner output in the grant year is itself an equilibrium object affected by pendency, workload, promotions, and other dynamics.
- If different examiners have systematically different pendency, then using grant-year output to proxy permissiveness introduces an additional channel through prosecution speed. The paper says that this is acceptable because the estimand is reduced-form, but then the causal interpretation shifts materially: it becomes the effect of assignment to an examiner with a different bundle of output/pendency/claims behavior, not examiner grant intensity per se.

The paper should either (i) embrace this broader estimand and stop analogizing so strongly to examiner-IV designs, or (ii) redesign using application-level data.

### D. The outcome definition is too aggregate relative to the treatment
The main outcome is the count of new granted Y02 patents in the same CPC subclass within 3 or 5 years after the focal patent’s grant date; mean 5-year follow-on count is about 26,620 (Summary Statistics table; Data section). This is an extremely aggregated subclass-time outcome, and many focal patents in the same subclass/date neighborhood share nearly the same dependent variable.

That creates two substantive concerns:

1. **Mismatch between individual-level treatment and aggregate-level outcome**: a single patent/examiner assignment is unlikely to move total subclass patenting counts materially unless effects are very large. A null at this level may simply reflect outcome dilution.

2. **Reflection/common-outcome problem**: many observations inherit essentially the same subclass-level count. Identification is then coming from cross-examiner variation among patents mapped into very similar aggregate outcomes, which can mechanically generate tiny coefficients even if patent-level follow-on effects exist.

The paper does note that cross-subclass spillovers could bias toward zero, but the deeper issue is that the chosen outcome may be too coarse to test the stated mechanism.

### E. Threats to identification are not adequately addressed
The paper lists threats (Empirical Strategy, “Threats to Validity”), but several are not really resolved:

- **Differential examiner workload/case assignment volume**: acknowledged, not addressed.
- **Selection into granted sample**: acknowledged indirectly, not addressed.
- **Examiner-specific pendency**: relevant because treatment is grant-year-based and outcome windows begin at grant; not addressed.
- **Shared outcomes within subclass-time cells**: not addressed in inference design.
- **Y02 retroactive coding and timing issues**: discussed, but implications for outcome construction are not fully explored.

In short, the identification strategy is not credible for the paper’s headline causal claim.

## 2. Inference and statistical validity

This is the second major weakness.

### A. Clustering at examiner level is likely not sufficient for the main outcome
The main outcome is subclass-level follow-on patent counts. Many patents in the same CPC subclass and similar grant periods share highly overlapping or identical outcomes. Yet the paper clusters at examiner level throughout (Empirical Strategy; Tables 2–5).

That is unlikely to be the correct dependence structure. Residual correlation should be expected at least at the subclass-by-time level, potentially also art-unit-by-time or grant-cohort-by-subclass level. Clustering only by examiner ignores the fact that outcome shocks are shared across many patents independent of examiner assignment.

The paper claims that art-unit-by-filing-year fixed effects “absorb the level of these subclass aggregates within each cell.” That is not correct as stated. Art-unit-by-filing-year FE do not absorb subclass-specific follow-on shocks unless subclass is nested in those FE in a very restrictive way, which is not established. Since the outcome is defined by CPC subclass, residual correlation at subclass-time remains a first-order concern.

The alternative clustering reported in Table 5 and Appendix Table A does not solve this:
- clustering by art unit or art-unit-by-year is not aligned with the outcome definition;
- no clustering by CPC subclass, subclass × cohort, or multiway clustering is shown.

For this paper to pass on inference, the authors need a dependence structure aligned to the outcome construction.

### B. The “precisely estimated null” claim is overstated until inference is repaired
The paper repeatedly emphasizes ruling out effects larger than ±0.5%. That conclusion depends entirely on the validity of the reported standard errors. Given the likely under-clustering problem, the CI is not yet credible.

This matters because the paper’s contribution is built around a null. Null papers can be important, but only when the design and inference are especially airtight. Here neither is sufficiently secure.

### C. The experienced-examiner result is not handled appropriately
Table 5 reports a marginally significant negative estimate for experienced examiners (-0.0042, s.e. 0.0025). The paper downplays this as “possible weak negative effect” not robust across specs. That is reasonable as far as it goes, but because the main identifying concern is measurement error in the treatment, the experienced-examiner sample is actually conceptually important. If the regressor is less noisy there, that estimate could be more informative than the baseline. The paper needs a clearer interpretation and formal comparison, not just a passing note.

### D. The IV-on-claims exercise is not publication-quality as presented
Appendix Table IV instruments log claims with examiner grant share. This analysis is not credible in current form:
- the instrument is not plausibly exogenous for claims for the same reasons as above;
- the exclusion restriction for claims is especially weak, since examiner assignment directly affects many aspects of prosecution besides claims;
- the paper itself cites many-instrument concerns, yet the exercise is underdeveloped;
- the first stage F = 38.2 is presented as “suggestive,” but the deeper issue is not only strength, it is validity.

This section should be removed or radically reframed.

## 3. Robustness and alternative explanations

### A. Robustness checks are not targeted at the key identification threat
The reported checks—Poisson, winsorization, large cells, alternative clustering, experienced examiners—do not address the main alternative explanation: that examiner grant share proxies workload/output volume among granted cases rather than permissiveness.

High-value omitted robustness analyses include:
- controls for examiner-year workload or total disposals, if available;
- restricting to examiners with stable assignment loads;
- within-examiner over-time designs;
- placebo outcomes not plausibly affected by the focal patent;
- using application-year rather than grant-year based treatment definitions if possible;
- demonstrating that high-share examiners do not simply receive more cases.

Without something along these lines, the current robustness section gives a false sense of security.

### B. Placebo/falsification exercises are missing or weak
A paper making a quasi-experimental claim should include stronger falsifications. For example:
- effect on pre-grant subclass trends or “leads” in follow-on activity;
- placebo outcomes in unrelated subclasses;
- tests using pseudo grant dates;
- randomization inference/permutation across examiners within cells.

None of these is presented.

### C. Mechanism claims are not sufficiently separated from reduced-form facts
The paper interprets the positive forward-citation effect as evidence that patents “attract attention” but do not change innovation trajectories. That is plausible, but citations are themselves affected by patent visibility, examiner citation practices, patent scope, applicant sophistication, and truncation. The mechanism discussion goes beyond what the evidence supports.

Similarly, policy discussion often slides from “assignment to a higher-output examiner has no detectable effect in this design” to “patents are not blocking green innovation.” That is too strong given the design limitations and the aggregate outcome.

### D. External validity is oversold
The paper often generalizes from marginal examiner-driven variation to broad policy claims about TRIPS waivers, compulsory licensing, and the binding constraints on climate innovation. But the design, even if valid, would identify a local reduced-form effect for marginal cases among granted U.S. patents in specific technology classes. That is very far from the effect of broad changes in IP regimes or global licensing policy.

## 4. Contribution and literature positioning

### Strength
The topic is timely and the paper does make an effort to bridge the patent-IV literature and the green innovation literature. The comparison to Sampat et al.-style designs is intuitive.

### Main issue
The paper overstates novelty and comparability to the examiner-IV literature. Because it lacks application-level denied/abandoned cases, it is not implementing the same design as Farre-Mensa, Sampat, or related work. It is implementing a looser granted-patents reduced form with a treatment proxy that conflates examiner permissiveness and output volume.

That does not make the exercise worthless, but the contribution should be repositioned much more modestly.

### Literature gaps / citations to add
The paper should engage more directly with modern critiques and methods for staggered quasi-experimental designs only if relevant; here the more important gap is in the examiner design literature and patent data limitations. Concrete additions:

1. **Abrams, Akcigit, and Popadak (2018/2019, examiner variation/patent examination)** — relevant for examiner heterogeneity and how examiner behavior affects outcomes beyond grant decisions.
2. **Frakes and Wasserman** on patent examination incentives and examiner behavior — highly relevant because workload/output may be endogenous to institutional incentives.
3. **Cunningham, Ederer, Ma (2021), “Killer Acquisitions”** is not directly about patents but useful for discussing how patenting may not map neatly to innovation. Optional.
4. **Kogan et al. (2017)** on patent value measures — useful if discussing citations versus substantive innovation.
5. More direct discussion of **PatEx / application-level datasets** and why prior papers could identify first stages that this paper cannot.

If there are exact foundational citations behind “Chyn 2024,” those should be carefully checked and supplemented with the canonical many-instrument / leave-one-out judge-IV references.

## 5. Results interpretation and claim calibration

This is an area where the paper needs substantial recalibration.

### A. The conclusion overreaches relative to the estimand
The paper concludes that “the marginal green patent neither blocks competitors nor stimulates additional inventive activity” and that “the patent system is a sideshow in the clean energy drama” (Conclusion). Those statements are not supported by the design.

At most, the paper shows that in a granted-only sample, a noisy measure of assigned examiner output share is not robustly associated with a very aggregated measure of same-subclass future granted patent counts, conditional on fixed effects. That is much narrower.

### B. The citation result is easier to generate than the paper suggests
The positive effect on forward citations may reflect:
- more visible or broader patents,
- different examiner practices,
- differences in grant timing/patent age,
- truncation or cohort composition,
- applicant characteristics not absorbed by the model.

The paper should not treat this as clean evidence of a “visibility channel” without more analysis.

### C. Magnitude interpretation is shaky because the treatment lacks a clear unit
A “one standard deviation increase in examiner grant share” is not a stable behavioral object. Since the treatment is a within-cell share of granted patents, its meaning varies with cell size and examiner staffing. The paper tries to interpret it as moving from the 25th to 75th percentile examiner, but that does not restore causal meaning. Magnitude statements should therefore be more cautious.

## 6. Actionable revision requests

### 1. Must-fix issues before acceptance

**1. Rebuild the identification strategy around application-level data, or radically narrow the claim.**  
- **Why it matters:** Without denied/abandoned applications, the main regressor does not identify examiner permissiveness and the sample conditions on a post-treatment outcome.  
- **Concrete fix:** Use PatEx or equivalent application-level data to construct true examiner grant rates and estimate a defensible first stage. If that is not possible, rewrite the paper as a descriptive reduced-form study of examiner output among granted patents and remove causal claims about patent grants, blocking, and examiner leniency.

**2. Repair inference for the main outcome.**  
- **Why it matters:** Examiner-level clustering is not aligned with an outcome defined at subclass-time aggregation, so the null may be spuriously precise.  
- **Concrete fix:** Re-estimate with clustering or randomization inference at the CPC subclass × grant-cohort / filing-cohort level, or use multiway clustering that includes outcome-sharing dimensions. At minimum, show robustness to subclass-level and subclass-time-level dependence structures.

**3. Address selection into the granted sample explicitly.**  
- **Why it matters:** Conditioning on grants invalidates balance tests and undermines causal interpretation.  
- **Concrete fix:** If application-level data are unavailable, provide a formal discussion showing what estimand remains under selection, and stop presenting balance on granted patents as evidence of random assignment. Ideally, move to the full application universe.

**4. Reassess the outcome design.**  
- **Why it matters:** The subclass-level aggregate outcome is too coarse relative to the treatment and creates shared-outcome inference problems.  
- **Concrete fix:** Add more targeted outcomes: citations by later green patents, follow-on by close text/technology neighbors, applicant-level or assignee-external follow-on, or patent-level measures of cumulative innovation. If subclass counts remain, defend them with stronger reasoning and appropriate inference.

### 2. High-value improvements

**5. Add falsification and placebo tests.**  
- **Why it matters:** These are essential for a quasi-experimental paper, especially one built on a null.  
- **Concrete fix:** Include pre-trend/lead tests, unrelated-subclass placebos, pseudo-treatment dates, and within-cell permutation/randomization inference.

**6. Probe the workload-versus-permissiveness channel.**  
- **Why it matters:** This is the core alternative explanation for the treatment proxy.  
- **Concrete fix:** Show whether examiner grant share predicts observable workload, pendency, or case volume; control for those where possible; compare results in settings with more stable examiner caseloads.

**7. Reframe or remove the patent-scope IV.**  
- **Why it matters:** In current form it distracts and is not convincing.  
- **Concrete fix:** Either drop it, or turn it into a clearly labeled exploratory appendix with explicit caveats about exclusion and instrument validity.

**8. Temper policy claims.**  
- **Why it matters:** The current interpretation extrapolates far beyond the design.  
- **Concrete fix:** Replace broad claims about TRIPS reform or the irrelevance of patents with narrower statements tied to the identified margin.

### 3. Optional polish

**9. Clarify the estimand consistently.**  
- **Why it matters:** The paper alternates between examiner leniency, grant intensity, grant share, and higher-output examiner.  
- **Concrete fix:** Pick one term and define exactly what is observed and what is not.

**10. Strengthen literature positioning around patent examination behavior.**  
- **Why it matters:** The current literature review leans too much on papers using stronger data/designs.  
- **Concrete fix:** Add examiner-incentive/workload papers and distinguish your setting sharply from canonical examiner-IV studies.

## 7. Overall assessment

### Key strengths
- Important, policy-relevant question at the intersection of innovation and climate.
- Large dataset and careful documentation of data construction.
- Welcome transparency that the design is reduced-form rather than a structural grant-effect estimate.
- The paper does not hide the main null and tries to interpret it thoughtfully.

### Critical weaknesses
- The central regressor is not a credible proxy for examiner permissiveness in the absence of application-level data.
- The sample is conditioned on granted patents, creating post-treatment selection.
- Balance tests do not validate random assignment in this selected sample.
- Inference likely understates uncertainty because clustering does not match the shared-outcome structure.
- The main outcome is too aggregate to cleanly test the theory, and the policy conclusions are substantially overclaimed.

### Publishability after revision
As written, I do not think the paper is close to acceptance. The issues are fundamental enough that a convincing version likely requires redesign with application-level data and a new inference strategy. If the authors cannot obtain those data, the paper could still become a useful descriptive or exploratory piece with much more modest claims, but that would be a different paper from the one currently presented.

DECISION: REJECT AND RESUBMIT